MAPT and Alzheimer disease: In addition, the biomarker testing was applied to monitor the state of AD progression by measuring the concentration of specific antibodies and proteins, including Aβ1-41, Aβ42/Aβ40, total tau protein (t-tau), and hyperphosphorylated tau protein (p-tau) in the cerebrospinal fluid or blood10,11.